ClinicalTrials.gg
Not yet recruitingNCT07707934MEDUpdated Nov 20, 2026

Methadone Expansion in Detention Though the Hospital/Clinic Designation

An interventional study of Learning Collaborative in Opioid Use Disorder, Incarcerated Individuals and Methadone Maintenance, sponsored by Brendan Saloner. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Brendan Saloner · Not applicable, Interventional, and Health services research

How we know

Updated Nov 20, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to improve implementation of hospital/clinic methadone in several carceral systems and study the effects of implementation on patient outcomes.

This study has four Aims:

  • Evaluate an intervention for carceral staff that will receive individual coaching and group didactic sessions focused on improving adoption and implementation of hospital/clinic methadone. Effects of this intervention will be measured via qualitative interviews and baseline, midpoint and final surveys of participants.
  • Apply a trial emulation approach to electronic health records from three prison systems currently using hospital/clinic methadone to evaluate the effect of implementation on the initiation and retention of medications for opioid use disorder treatment.
  • Link Medicaid data to electronic health records from one prison system implementing hospital/clinic methadone to examine the effect of implementation on post-release outcomes, including MOUD use and broader healthcare utilization.
  • Examine the cost effectiveness and budgetary impact of implementing hospital/clinic methadone.
Read the detailed description

Incarcerated persons have a high prevalence of opioid use disorder (OUD), and risk of fatal and nonfatal overdose surges immediately following release. Providing medications for OUD (MOUD) during and following incarceration is a proven strategy for reducing overdose risk, yet few facilities offer MOUD. Of the three MOUDs approved by the Food and Drug Administration, methadone is particularly challenging for carceral facilities to provide because it typically can be dispensed only by federally-accredited and certified opioid treatment programs (OTPs). Very few carceral facilities have created onsite OTPs, citing the costly, time-intensive process as a barrier to uptake. Other facilities do not provide methadone or offer limited methadone through partnerships with community-based OTPs. This is often not feasible in rural areas without OTPs, where many carceral facilities are located. Expanding access to carceral methadone is of key public health importance, because it is the optimal treatment for some patients, particularly those with high opioid tolerance associated with use of fentanyl and its analogs.

In 2024, the Substance Abuse and Mental Health Services Administration (SAMHSA) released updated 42 CFR Part 8 rules, which clarified that any carceral facility registered as a "hospital/clinic" with the Drug Enforcement Administration (DEA) is permitted to stock and dispense methadone for the treatment of OUD, as long as the patient is primarily being treated for another medical condition. Given the high prevalence of comorbidities and the opportunity to provide methadone outside of OTPs, the hospital/clinic designation could dramatically expand access to MOUD for incarcerated persons. However, implementation also requires carceral systems to engage with potentially unfamiliar processes, such as applying for the hospital/clinic designation, stocking and dispensing methadone, and initiating and maintaining methadone treatment. Through a technical assistance partnership with our team, three state departments of corrections (DOCs) - Colorado, Delaware, and Washington - are the first jurisdictions to implement the hospital/clinic designation for this purpose, each at different stages of implementation. Given the recency of the hospital/clinic designation rules, there is need to understand how these vanguard DOCs are implementing, how adoption affects OUD-related outcomes during and after incarceration, and the cost-effectiveness of this process, all of which can inform future adoption of this novel approach for methadone provision.

Working in partnership with these vanguard DOCs, the overarching goal of this five-year JCOIN project is to generate research evidence that can support the broader implementation of methadone in carceral facilities using the hospital/clinic designation. We will conduct a mixed-methods study that engages early adopter facilities in a learning collaborative that will blend didactic education and applied problem-solving, evaluating implementation outcomes via surveys and qualitative interviews (Aim 1). We will use 2022-2028 carceral health records from all three vanguard DOCs to study OUD-related outcomes during incarceration (Aim 2). We will link carceral health records with post-release Medicaid data in the Washington DOC to examine post-release OUD outcomes (Aim 3) and conduct a cost-effectiveness evaluation (Aim 4). Our study is guided by the substance use treatment framework, the Behavioral Cascade of Care, and the implementation outcomes framework, RE-AIM. Our study aims are as follows:

Aim 1: Engage early implementers in a learning collaborative to improve reach, adoption, and implementation of the hospital/clinic designation. Hypothesis: The learning collaborative will improve the reach and adoption of methadone via the hospital/clinic designation and help navigate potential challenges, such as stigma towards MOUD, establishing methadone stocking and dispensing protocols, staffing, reentry planning and coordination between security and medical staff.

Aim 2: Identify the effect of the hospital/clinic designation on initiation and retention for MOUD treatment during incarceration. Hypothesis: The hospital/clinic designation will result in improved overall initiation and retention of MOUD in the Colorado, Delaware and Washington DOCs.

Aim 3: Examine the effect of the hospital/clinic designation on post-release care for opioid use disorder and chronic health conditions. Hypothesis: Use of the hospital/clinic designation will result in improved post-release use of methadone and chronic condition management, and decreased incidence of overdose in the year following release. Effects will vary by reentry county characteristics.

Aim 4: Calculate the cost, cost-effectiveness, and budgetary impact of carceral methadone treatment delivered via the hospital/clinic designation. Hypothesis: Use of the hospital/clinic designation will be cost-effective and affordable within the resources of each DOC compared to the status quo where methadone is only obtained from OTPs.

Study results will inform decisions about current and future adoption of this important new option for expanding methadone access in carceral facilities, with the potential to have huge lifesaving effects on a marginalized population.

02

Conditions studied

  • Opioid Use Disorder
  • Incarcerated Individuals
  • Methadone Maintenance
03

In context

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

This study's planned enrollment of 30 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.

Browse Opioid-Related Disorders studies →

Lead sponsor

This is the only study on the registry with Brendan Saloner as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Employee of a carceral system interested in or implementing the hospital/clinic designation
  • Involved in security, medical, or budget/administrative aspects of the carceral system

Exclusion criteria

Exclusion Criteria:

  • Does not meet inclusion criteria above
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Learning Collaborative

    All participants will receive individual and group coaching sessions

    Other: Learning Collaborative

Interventions

  • OtherLearning Collaborative

    All participants will receive individual and group coaching sessions to facilitate implementation of the hospital/clinic designation.

06

What researchers measure

Primary outcomes

  1. Patients on methadone through h/c

    Number of patients receiving methadone via the hospital/clinic designation

    Time frame: At baseline, at month 12, and at month 24

Secondary outcomes

  1. Implementation outcomes assessment

    Implementation Outcomes Assessment from Weiner et al., 2017. doi:10.1186/s13012-017-0635-3. The three measures from this assessment will be combined into one measure.

    Time frame: At baseline, at month 12, and at month 24

  2. Staff Attitudes Towards MOUD

    Knudsen et al., 2005's Staff Attitudes Towards MOUD measure. doi:10.1016/j.jsat.2005.05.002

    Time frame: At baseline, at month 12, and at month 24

  3. Organizational Readiness for Implementing Change

    Shea et al., 2014's Organizational Readiness for Implementing Change measure. doi:10.1186/1748-5908-9-7

    Time frame: At baseline, at month 12, and at month 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For participants who consent to data sharing, de-identified survey and interview data will be deposited into the HEAL data repository.

Supporting information: Study protocol, Informed consent form, Analytic code

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for Sep 2029, 27 months later.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 27 months is close to that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Sep 2026 → Jun 2027 and primary completion Sep 2028 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jul 16, 2026
StartEst.
Jun 2027was Sep 2026
Primary completionEst.
Sep 2029was Sep 2028
CompletionEst.
May 31, 2030
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Jun 2027
Nov 20, 2026
Primary completion
Sep 2028→Sep 2029
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Start date Sep 2026→Jun 2027
    Primary completion Sep 2028→Sep 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07707934
Lead sponsor
Brendan Saloner
Responsible party
Brendan Saloner (Donald G. Millar Distinguished Professor of Alcohol and Addiction Studies, Brown University) — Sponsor-investigator
First posted
Jul 16, 2026
Start date
Jun 2027 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Nov 20, 2026

Study contacts

Brendan Saloner, PhD
Contact
brendan_saloner@brown.edu
401-863-2228

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion